drugset / Trial / NCT01593228

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

NCT01593228

Phase 3 Completed 37 enrolled Sanofi
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability of iniparib administered as monotherapy or in combination regimens in patients previously treated with iniparib in a clinical study and who have derived clinical benefit after completion of the parental study's objectives.

Timeline

Start
2012-05
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Iniparib Small molecule Intravenous
Background Carboplatin Small molecule Intravenous
Background Doxorubicin Other / unclassified Intravenous
Background Gemcitabine Small molecule Intravenous
Background Irinotecan Small molecule Intravenous
Background Paclitaxel Small molecule Intravenous
Background Topotecan Small molecule Intravenous

Indications